GT Biopharma Inc
NASDAQ:GTBP
GT Biopharma Inc
NASDAQ:GTBP
Price:
3.53 USD
-4.08%
Market Closed
Updated:
May 29, 2024
GT Biopharma Inc
Income from Continuing Operations
|
GT Biopharma Inc
Income from Continuing Operations Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
GT Biopharma Inc
NASDAQ:GTBP
|
Income from Continuing Operations
-$9.6m
|
CAGR 3-Years
47%
|
CAGR 5-Years
48%
|
CAGR 10-Years
-21%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$456m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is GT Biopharma Inc's Income from Continuing Operations?
Income from Continuing Operations
-9.6m
USD
-9.6m
USD
Based on the financial report for Mar 31, 2024, GT Biopharma Inc's Income from Continuing Operations amounts to -9.6m USD.
What is GT Biopharma Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-21%
-21%
Over the last year, the Income from Continuing Operations growth was 38%. The average annual Income from Continuing Operations growth rates for GT Biopharma Inc have been 47% over the past three years , 48% over the past five years , and -21% over the past ten years .
You don't have any saved screeners yet
